Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis
Michael C. Nevitt(University of California, San Francisco), John H. Krege(Eli Lilly (United States)), José Zanchetta(Universidad del Salvador), Robin K. Dore(University of California, Los Angeles), Emmett V. Glass(Eli Lilly (United States)), P. Chen(Eli Lilly (United States)), J.-Y. Reginster(University of Liège), Douglas P. Kiel(Harvard University)
Cited by 55
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
The FNIH Sarcopenia Project: Rationale, Study Description, Conference Recommendations, and Final Estimates
|The Journals of Gerontology Series A|2014|2.5k
Generation and reproductive phenotypes of mice lacking estrogen receptor β
|Proceedings of the National Academy of Sciences|1998|1.7k